Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers

We examined the effects of LJM716, a HER3 (ERBB3) neutralizing antibody that inhibits ligand-induced and ligand-independent HER3 dimerization, as a single agent and in combination with BYL719, an ATP competitive, p110α-specific inhibitor against HER2-overexpressing breast and gastric cancers. Treatm...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Garrett, Joan T., Sutton, Cammie R., Kurupi, Richard, Bialucha, Carl Uli, Ettenberg, Seth A., Collins, Scott D., Sheng, Qing, Wallweber, Jerry, DeFazio-Eli, Lisa, Arteaga, Carlos L.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2013
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3790862/
https://ncbi.nlm.nih.gov/pubmed/23918797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1191
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk